NeuroPace Reports 'Minimal Impact' From Trump Tariffs
NeuroPace Expects No Material Impact on Gross Margin for DIXI Medical SEEG Products >NPCE
NeuroPace: Manufactures and Sells the Vast Majority of Its Devices in United States >NPCE
NeuroPace Has Limited Supply Chain Activities Outside United States for Its RNS System >NPCE
Express News | Neuropace Inc - Reiterates Gross Margin Guidance for 2025
Express News | Neuropace Inc - Expects Minimal Impact From Tariffs
NeuroPace Provides Update on Tariff Status
Cantor Fitzgerald Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $17
Cantor Fitzgerald Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $17
Kura Sushi Posts Downbeat Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $17
Leerink Partners Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $18
Wells Fargo Remains a Buy on NeuroPace (NPCE)
Stryker, Boston Scientific Down as New Tariffs Impact Medtech Industry
NeuroPace (NPCE) Receives a Buy From Lake Street
Express News | Neuropace Announces Upcoming Oral Presentation of Data From the Long-Term Post-Approval Study of the Rns System at the 2025 Aan Annual Meeting
NeuroPace Announces Upcoming Oral Presentation of Data From the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
NeuroPace to Terminate Distribution Relationship for Seeg Products
Express News | Neuropace Inc: Beginning of Wind Down of Stereo Eeg (Seeg) Distribution Relationship in Q4 2025